الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
Ventilator-associated pneumonia (VAP) remains one of the most common ICU acquired infections and is associated with greater ICU length of stay, mortality, and healthcare costs (Restrepo et al., 2010). Inadequate initial antimicrobial treatment of VAP is associated with adverse outcomes however, early adequate therapy is increasingly more difficult to achieve (Kollef KE et al., 2008; Chung et al., 2011). Intravenously administered antibiotics are primarily detected in respiratory segments of lungs, but not in sputum in contrast antibiotics administration offers the theoretical advantages of achieving high drug concentrations at the infection site and low systemic absorption (Hoiby, 2011; Dhand, 2007). In the present study, we assessed the efficacy and safety of nebulized (ceftazidime plus amikacin) as adjunctive to systemic antibiotics in treatment of ventilator associated pneumonia during ICU stay. This study was conducted on sixty patients who were admitted to critical care department in Benha university hospitals and diagnosed with Ventilator Associated Pneumonia (VAP). All patients were allocated in two groups as follows: group A: Thirty patients with VAP and received only systemic antibiotics